Anzeige
01.06.2023 | Review
Impact of ezetimibe on markers of inflammation in patients treated with statins: a systematic review
Erschienen in: Inflammopharmacology | Ausgabe 4/2023
Einloggen, um Zugang zu erhaltenAbstract
Statins are the primary pharmacological intervention to reduce LDL cholesterol; they significantly reduce inflammatory markers. Ezetimibe also reduces LDL cholesterol and reduces cardiovascular events when given on top of statin therapy. Whether ezetimibe, like statins, reduces markers of inflammation is less clear. We, therefore, conducted a systematic literature research addressing the impact of ezetimibe on CRP, TNFα and IL-6 when given on top of statin therapy. Our work indicates that overall ezetimibe reduces inflammation on top of statin treatment. However, available data are limited for CRP and even more so for TNFα and IL-6.